Intra-cardiac distribution of late gadolinium enhancement in cardiac sarcoidosis and dilated cardiomyopathy

Table 2 Clinical features and magnetic resonance imaging parameters in patients with cardiac sarcoidosis and with dilated cardiomyopathy

	CS	DCM	P values
Number	14	30
Sex (M/F)	M4/F10	M23/F7	0.001
Age (yr)	59.8 ± 13.5	69.2 ± 12.6	0.03
Syncope n (%)	2 (14.3)	6 (20.0)	0.65
Palpitation n (%)	7 (50.0)	17 (56.7)	0.74
NYHA (I/II/III/IV)	8/5/1/0 (57.1%/35.7%/ 7.1%/0%)	8/11/6/5 (26.7%/36.7%/ 20%/16.7%)	0.08
ECG findings
PQ duration	188.4 ± 26.0	188.1 ± 40.9	0.91
1st/2nd AVB	7/1 (50.0%/7.1%)	7/0 (23.3%/0%)	0.14
QRS duration	118.6 ± 22.9	128.4 ± 36.3	0.18
Abnormal Q waves n (%)	6 (42.9)	3 (10.0)	0.09
RBBB/LBBB	3/5 (21.4%/35.7%)	2/15 (6.7%/50%)	0.57
VTs n (%)	7 (50.0)	15 (50.0)	0.74
Medications n (%)
Corticosteroids	7 (50.0)	0 (0)	< 0.001
ACEI/ARB	9 (64.3)	20 (66.7)	0.73
β blockers	7 (50.0)	23 (76.7)	0.07
AADs	4 (28.6)	14 (46.7)	0.51
Diuretics	7 (50.0)	18 (60.0)	0.32
MRI
LVEDVI (mL/m2)	107.0 ± 45.8	135.5 ± 43.4	0.08
LVESVI (mL/m2)	74.2 ± 44.5	106.3 ± 42.1	0.04
LVMI (g/m2)	60.1 ± 24.9	67.1 ± 28.9	0.34
LVEF (%)	33.9 ± 11.0	22.8 ± 10.0	0.003
LE segment number	8.6 ± 4.6	5.3 ± 3.1	0.04

The categorical variables were expressed as number and percentage (%) and compared by χ² test. The continuous variables were expressed as means ± SD and examined by unpaired t test. CS: Cardiac sarcoidosis; DCM: Dilated cardiomyopathy; M/F: Male/female; NYHA: New York Heart Association; ARB: Angiotensin receptor blockers; ACEI: Angiotensin converting enzyme inhibitors; AVB: Atrioventricular block; AAD: Anti-arrhythmic drugs; MRI: Magnetic resonance imaging; LVEDVI and LVESVI: Left ventricular end-diastolic and end-systolic volume indices; LVEF: LV ejection fraction; LE: Late gadolinium enhancement; L/RBBB: Left/right bundle branch blocks; LVMI: LV mass index; VT: Ventricular tachycardia.